Document is current
Any future updates will be listed below
-
Authors
Sam, Ikuan
Benhamouda, Nadine
Biard, Lucie
Da Meda, Laetitia https://orcid.org/0000-0003-2988-6792
Desseaux, Kristell
Baroudjan, Barouyr
Nakouri, Ines
Renaud, Marion
Sadoux, Aurélie
Alkatrib, Marina
Deleuze, Jean-François https://orcid.org/0000-0002-5358-4463
Battistella, Maxime
Shen, Yimin
Resche-Rigon, Matthieu
Mourah, Samia
Lebbe, Celeste https://orcid.org/0000-0002-5854-7290
Tartour, Eric https://orcid.org/0000-0002-7323-468X
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (PRTK)
Agence Nationale de la Recherche (PC SI 2021)
Agence Nationale de la Recherche (ANR-18-IDEX-0001,France 2030)
Region Ile de France (DIM-ITAC)
- License Information
-
More Information
Article History
Received: 26 October 2024
Revised: 25 January 2025
Accepted: 10 February 2025
First Online: 27 March 2025
Disclosure and competing interests statement
: Celeste Lebbe: Consulting fees: BMS, Pierre Fabre, Sanofi, Novartis, MSD, Amgen, Merck, Serono, Roche, Inflax. Payment of honoraria for lectures, présentations, speakers bureaux: Amgen, BMS, Pierre Fabre, Sanofi, Novartis, MSD, Incyte, Pfizer, Roche. Support for attending meeting and or travel: BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi. Participation on a data safety monitoring board or advisory board: BMS, Pierre Fabre, Sanofi, Novartis, MSD, Amgen, Merck Serono, Roche, Inflax. Research funding institution: BMS, Roche. Eric Tartour: Research contract: Servier, Oseo Pharma, Imcheck Therapeutics. Payment of honoraria for lectures, présentations, speakers bureaux: Sanofi, BMS, Merck-MSD, Olimpe. Participation of Advisory Board: BMS, Astra-Zeneca, Moderna, Amgen.
